Alpha Crest Capital Management LLC Fibrogen Inc Transaction History

Alpha Crest Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $109,326 - $140,014	-9,590 Reduced 13.83%	59,748 $777,000
Q2 2022 Aug 11, 2022	BUY	$7.94 - $12.96 $385,018 - $628,443	48,491 Added 232.6%	69,338 $732,000
Q1 2022 May 12, 2022	BUY	$12.02 - $16.79 $250,580 - $350,021	20,847 New	20,847 $251,000
Q3 2021 Nov 10, 2021	SELL	$10.18 - $26.64 $104,854 - $274,392	-10,300 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$18.57 - $35.68 $191,271 - $367,504	10,300 New	10,300 $274,000
Q4 2020 Feb 12, 2021	SELL	$37.09 - $48.97 $504,424 - $665,992	-13,600 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$40.47 - $45.5 $550,392 - $618,800	13,600 New	13,600 $559,000
Q4 2019 Feb 12, 2020	SELL	$34.58 - $48.06 $331,968 - $461,376	-9,600 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$36.98 - $48.45 $355,007 - $465,120	9,600 New	9,600 $355,000
Q2 2019 Aug 12, 2019	SELL	$35.13 - $55.53 $182,676 - $288,756	-5,200 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$42.83 - $59.91 $222,716 - $311,532	5,200 New	5,200 $283,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.